For years, pharma treated customer experience as a healthcare provider problem. Get the HCP touchpoints right, coordinate the field rep with the email with the conference booth, and the rest would follow. That assumption is breaking down.
Patients today research their own conditions, compare treatment options online, join patient communities before their first specialist appointment, and expect the same convenience from a pharma brand that they get from their bank or their airline. In 2026, the companies pulling ahead on customer experience are the ones treating patients and caregivers as consumers in their own right, not as a downstream audience for messages designed for doctors.
The Gap Pharma Can’t Out-Market Its Way Through
The starting point for any honest conversation about pharma CX is a gap most companies don’t like to admit exists.
A global Deloitte survey of healthcare professionals and pharma executives found that 82% of life sciences leaders are satisfied with their current customer engagement strategies, while only 28% of the HCPs on the receiving end feel those strategies actually meet their needs. That’s not a small measurement error. That’s two groups looking at the same set of programs and reaching opposite conclusions.
The same disconnect shows up on the consumer side, just with less data collected on it historically. Patients report being handed conflicting information across a pharmacy visit, a support-program call center, and a branded website. Each channel was built by a different team, on a different timeline, often without much visibility into what the other channels were saying. The result feels less like a coordinated relationship and more like three separate companies that happen to share a logo.
No amount of marketing spend fixes that problem. Consumers don’t experience organizations through org charts. They experience them one interaction at a time.
Consumers Didn’t Just Start Paying Attention. They Started Comparing.
The consumer angle matters more in 2026 because patients now hold pharma to a bar set by industries with nothing to do with healthcare. Someone who orders groceries with two taps and gets same-day delivery, or resolves a billing dispute over chat in ten minutes, brings those expectations into a conversation about their medication.
When a patient support program still requires a phone call during business hours, or a prior-authorization process that takes weeks and offers zero visibility into status, the frustration isn’t really about pharma. It’s about pharma falling short of a standard the patient already has in mind from everywhere else in their life.
Healthcare is no longer competing only with healthcare. Every digital experience people have during the day quietly resets their expectations for the next one.
Four Consumer Shifts Every Pharma Organization Should Be Planning For
- Direct-to-consumer trust is now doing real work.
Deloitte’s research on trust dynamics found that consumers rank doctors as their most trusted source of health information by a wide margin, well ahead of pharma companies themselves.
That means a consumer-facing CX strategy built purely on brand messaging will continue to underperform. The more durable play is supporting the doctor-patient conversation with better tools, clearer information, and experiences that strengthen trust rather than trying to replace it.
- “Beyond the pill” support is now table stakes.
Patient support programs that once felt like value-added services—refill reminders, financial assistance navigation, symptom trackers, caregiver resources—are increasingly what patients expect by default.
A therapy that ships with a confusing enrollment process and no clear point of contact reads as a worse product, even if its clinical profile is identical to a competitor’s. Patients rarely separate the medicine from the experience surrounding it. Increasingly, they judge both together.
- Health equity is a customer experience issue.
Access barriers such as language, literacy, broadband access, transportation, or insurance literacy show up first as poor customer experiences.
A form someone cannot complete. A patient portal that doesn’t work on an older phone. A call center without interpreter support. These aren’t separate health equity initiatives. They’re customer experience failures. Organizations that continue treating accessibility as a compliance exercise rather than a design principle will continue leaving patients behind.
- Caregivers are a second consumer audience hiding inside the first.
A meaningful share of patient-support interactions are actually handled by spouses, adult children, or caregivers supporting someone who is elderly, seriously ill, or newly diagnosed.
Programs designed with only the patient in mind quietly fail this audience. And with it, they fail a significant part of real-world adherence. Caregivers often become the operational managers of healthcare. Ignoring them means ignoring the people who frequently determine whether treatment plans are actually followed.
The Consumer Is No Longer an Afterthought
For years, pharma invested heavily in HCP engagement while consumer experience evolved more slowly. That made sense when physicians remained the primary gatekeepers to information. Today’s patient journey looks very different. Patients arrive at appointments informed, connected, and carrying expectations shaped by every digital experience they’ve had outside healthcare. Improving customer experience in 2026 is no longer about building one more app or launching another patient support program. It’s about recognizing that patients and caregivers evaluate healthcare experiences the same way they evaluate every other service they use.
The organizations that understand this shift won’t simply create better digital experiences. They’ll build stronger trust, improve adherence, reduce friction, and create relationships that extend well beyond the prescription itself. The consumer angle is no longer an optional layer added after HCP strategy.
It has become one of the strategy’s defining elements.
Sources
- Deloitte. Unlocking the Future of Customer Engagement in Pharma
- DT Consulting. State of Customer Experience in the Global Pharmaceutical Industry
- PwC Health Industries. Customer Engagement Research
- McKinsey & Company. Life Sciences Omnichannel Research
If this area interests you further or are interested to be part of the 2026 Pharma CX Marketing Summit in October, please do get in touch with us.